Menu

Recent Interviews

Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

jared.scharf@desertgold.ca

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential


Stephan Dorfmeister, Finance Department, Deep Nature Project GmbH

Stephan Dorfmeister
Finance Department | Deep Nature Project GmbH
Untere Hauptstraße 168, 7122 Gols (AT)

office@deep-nature.at

+43 681 10139055

Like Aurora Cannabis and Canopy Growth, Deep Nature Project GmbH focuses on value chain


Alison Coutts, Executive Chairman, Memphasys Ltd.

Alison Coutts
Executive Chairman | Memphasys Ltd.
30 Richmond Road, 2140 Homebush West (AUS)

alison.coutts@memphasys.com

+61 2 8415 7300

Memphasys Executive Chairman Alison Coutts on in vitro fertilisation (IVF)


04. February 2020 | 05:50 CET

Aurora Cannabis, EXMceuticals, Tilray - Cannabis development in Portugal

  • Cannabis

From the street to the clinic. Cannabis had the image of an illegal street drug in most rich countries since the prohibition in the USA in the 1930s. Although cannabis has been used as a medicinal plant for more than 1,000 years, the past decades have been marked by other pharmaceutical products. The market and attitudes towards cannabis are now changing. Doctors, patients, companies and investors see opportunities to profit from this development.

time to read: 1 minutes by Mario Hose


 

Education is the key to success

Education and research are often the beginning of a success story. In order for development to progress, knowledge and education are an elementary basis for medical change with cannabis. Doctors, patients and companies must work together to test and evaluate the effects of cannabis in medicine.

With increasing experience and information in databases the acceptance of cannabis in medicine will increase. Thus the use of medical cannabis preparations can be suggested by physicians or simply demanded by patients.

Improvement of the quality of life

The use of and experiences with cannabis products are characterized by objective and subjective characteristics. For example, a cannabis product may cause a patient to sleep much better but not to feel any improvement in pain relief. The bottom line, however, is that the quality of life has subjectively increased due to improved sleep.

Such developments in practice ensure that cannabis products are accepted in medicine. In this context, however, it is important that patients have easy access to medical cannabis products and also that doctors know what they are prescribing for which therapies.

Opportunities for investors

Also the companies invest in the development of the cannabis market and here especially experience counts. Aurora Cannabis, EXMceuticals and also Tilray have different approaches and strategies to conquer the market for cannabis products.

For investors there is the opportunity to participate in the listed companies to be part of it. Even if the share prices of most cannabis companies have been declining in recent months, the trend in use and therapy will continue. It will probably only be a matter of time when this development will be reflected in the stock market prices again.

Portugal as cannabis centre

EXMceuticals, a manufacturer of high quality cannabis extracts for use in the pharmaceutical and nutraceutical industry as well as in therapy and cosmetics, announced yesterday that Prf. Dr. Eurico Castro Alves has been appointed to the company's advisory board.

Commenting on the appointment, Jonathan Summers, CEO of the company, said: "He and EXM share a common goal to establish Portugal as a centre for medical Cannabis healthcare and science. The next step is to have in operation, and licensed, a high-quality ingredients factory that will produce to medical standards and have many industrial applications.”


Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold shares in the aforementioned companies and that there may therefore be a conflict of interest. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

19. May 2020 | 15:02 CET

Aphria, Aurora Cannabis, Canopy Growth, EXMceuticals - do not miss the entry!

  • Cannabis

The nationwide and anonymous advertising format of Deutsche Post is called POSTAKTUELL and is published regularly in large print runs. The stack of advertising is wrapped in a foil and the practical added value for the recipient is the TV guide. The front of POSTAKTUELL is particularly eye-catching and anyone who advertises there will reach a lot of people. In the meantime, advertising for products and applications with active ingredients from the cannabis plant is already being done there. CBD reaches the general public and despite the Corona Pandemic, the industry's stocks are running in turnaround mode and have left the lows.

Read

23. March 2020 | 15:00 CET

Aurora Cannabis, Bayer, EXMceuticals - ready for the time after Corona

  • Cannabis

The cannabis hype was over and then came the corona crisis. Investors who believed in the active ingredient of cannabis and put money into the shares of companies in this industry are now likely to be sitting on a huge loss in most cases. It all started with the idea of a few companies to make one of the oldest medicinal plants in the world acceptable for general use within the framework of legalization. However, high margins and a large market soon led to competition and a brokerage industry was earning a lot of money - soon several hundred cannabis companies were listed on the stock exchange.

Read

25. February 2020 | 13:38 CET

Aurora Cannabis, Canopy Growth, EXMceuticals - who will be the best turnaround story?

  • Cannabis

Cannabis shares are not in demand at the moment. About a year ago the growth potential and possibilities of the rediscovered historical medicinal plant seemed to be endless. Today it is different, there is a hangover mood. The hype back then led to a buyer's market. Investors underbid each other with purchase orders and shareholders surrendered their shares in a nervous mood in order to set off for new shores. This or something similar may be the current situation in the environment of numerous cannabis companies. But experienced investors also know that consolidation phases are the foundation for success stories.

Read